| 1 | Patent Foramen Ovale Percutaneous Closure: Evolution and Ongoing Challenges | 1.8 | 15 | Citations (PDF) |
| 2 | Prognostic impact of peripheral artery disease in patients with and without high bleeding risk undergoing percutaneous coronary intervention | 1.1 | 4 | Citations (PDF) |
| 3 | TAVR Procedure-Related Stroke | 1.9 | 0 | Citations (PDF) |
| 4 | Transcatheter Mitral Valve Replacement for Valve-in-Ring | 1.9 | 1 | Citations (PDF) |
| 5 | Antiplatelet Therapy, Pretreatment, and Primary PCI | 6.3 | 1 | Citations (PDF) |
| 6 | Antithrombotic therapy for transcatheter structural heart intervention. | 2.2 | 12 | Citations (PDF) |
| 7 | Flecainide to Prevent Atrial Arrhythmia after Patent Foramen Ovale Closure, the AFLOAT Study: A Randomized Clinical Trial | 13.2 | 18 | Citations (PDF) |
| 8 | Transcatheter Patent Foramen Ovale Closure in Patients With Transient Ischemic Attack | 1.5 | 6 | Citations (PDF) |
| 9 | Impact of complex percutaneous coronary intervention features on clinical outcomes in patients with or without chronic kidney disease | 1.1 | 4 | Citations (PDF) |
| 10 | Impact of the antiplatelet strategy following patent foramen ovale percutaneous closure. | 2.6 | 17 | Citations (PDF) |
| 11 | Transcatheter Mitral Valve Replacement Using Transcatheter Aortic Valve or Dedicated Devices: Current Evidence and Future Prospects | 1.8 | 13 | Citations (PDF) |
| 12 | Comparison of three echo-guidance techniques in percutaneous patent foramen ovale closure for stroke prevention: Conventional transoesophageal, microprobe transoesophageal and intracardiac echocardiography | 0.4 | 5 | Citations (PDF) |
| 13 | Sex Differences in Patients With Cryptogenic Cerebrovascular Events Undergoing Transcatheter Closure of Patent Foramen Ovale | 3.1 | 13 | Citations (PDF) |
| 14 | Bioprosthetic leaflet thrombosis and reduced leaflet motion after transcatheter aortic valve replacement: A systematic review and meta-analysis | 0.4 | 7 | Citations (PDF) |
| 15 | Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials | 7.2 | 163 | Citations (PDF) |
| 16 | White blood cell count and clinical outcomes after left main coronary artery revascularization: insights from the EXCEL trial : Coronary Artery Disease | 1.2 | 0 | Citations (PDF) |
| 17 | Altered cardiac reserve is a determinant of exercise intolerance in sickle cell anaemia patients. | 2.2 | 11 | Citations (PDF) |
| 18 | Outcomes Following Patent Foramen Ovale Percutaneous Closure According to the Delay From Last Ischemic Event. | 1.5 | 10 | Citations (PDF) |
| 19 | Impact of transit-time flow measurement on early postoperative outcomes in total arterial coronary revascularization with internal thoracic arteries: a propensity score analysis on 910 patients. | 0.8 | 5 | Citations (PDF) |
| 20 | Timing of invasive management of NSTE-ACS: is the time up for early management? | 7.2 | 5 | Citations (PDF) |
| 21 | Antithrombotic Therapy Following Transcatheter Aortic Valve Replacement | 1.8 | 21 | Citations (PDF) |
| 22 | Clinical and echocardiographic risk factors for device-related thrombus after left atrial appendage closure: an analysis from the multicenter EUROC-DRT registry | 1.4 | 27 | Citations (PDF) |
| 23 | Transcatheter Closure of Patent Foramen Ovale in Older Patients With Cryptogenic Thromboembolic Events | 3.3 | 46 | Citations (PDF) |
| 24 | A Multi-Biomarker Score for a Global Approach of Risk | 6.3 | 2 | Citations (PDF) |
| 25 | Two-year clinical outcomes after successful transcatheter aortic valve implantation with balloon-expandable versus self-expanding valves: A subanalysis of the GALILEO trial | 1.1 | 7 | Citations (PDF) |
| 26 | Sirolimus-coated balloon versus everolimus-eluting stent in de novo coronary artery disease: Rationale and design of the TRANSFORM II randomized clinical trial | 1.1 | 49 | Citations (PDF) |
| 27 | TAVI : Apport du scanner dans le choix de la valve | 0.2 | 1 | Citations (PDF) |
| 28 | Side branch fractional flow reserve after provisional stenting of calcified bifurcation lesions: The ORBID-FFR study | 1.1 | 4 | Citations (PDF) |
| 29 | One-year clinical outcomes in patients with chronic kidney disease treated with COMBO stents: From the COMBO collaboration | 1.1 | 0 | Citations (PDF) |
| 30 | Life-threatening and major cardiac events during long-distance races: updates from the prospective RACE PARIS registry with a systematic review and meta-analysis | 1.5 | 32 | Citations (PDF) |
| 31 | Clinical Outcomes According to ECG Presentations in Infarct-Related Cardiogenic Shock in the Culprit Lesion Only PCI vs Multivessel PCI in Cardiogenic Shock TrialChest, 2021, 159, 1415-1425 | 0.8 | 9 | Citations (PDF) |
| 32 | Prevalence and prognostic impact of hsCRP elevation are age-dependent in women but not in men undergoing percutaneous coronary intervention | 1.1 | 3 | Citations (PDF) |
| 33 | Antithrombotic Therapy in Acute Coronary Syndromes: Current Evidence and Ongoing Issues Regarding Early and Late Management | 2.3 | 13 | Citations (PDF) |
| 34 | Predictive Value of the Residual SYNTAX Score in Patients With Cardiogenic Shock | 6.3 | 32 | Citations (PDF) |
| 35 | Impact of chronic total occlusion and revascularization strategy in patients with infarct-related cardiogenic shock: A subanalysis of the culprit-shock trial | 1.8 | 16 | Citations (PDF) |
| 36 | Clinical manifestations and outcomes of coronavirus disease-19 in heart transplant recipients: a multicentre case series with a systematic review and meta-analysis. | 1.7 | 9 | Citations (PDF) |
| 37 | Impact of renal function in high bleeding risk patients undergoing percutaneous coronary intervention: a patient-level stratified analysis from four post-approval studies | 1.1 | 4 | Citations (PDF) |
| 38 | Device-Related Thrombus After Left Atrial Appendage Closure: Data on Thrombus Characteristics, Treatment Strategies, and Clinical Outcomes From the EUROC-DRT-Registry | 3.3 | 104 | Citations (PDF) |
| 39 | Impact of sex on long-term cardiovascular outcomes of patients undergoing percutaneous coronary intervention for acute coronary syndromes | 1.1 | 7 | Citations (PDF) |
| 40 | Incidence, predictors and clinical impact of permanent pacemaker insertion in women following transcatheter aortic valve implantation: Insights from a prospective multinational registry | 1.1 | 9 | Citations (PDF) |
| 41 | Bleeding in the Elderly: Risk Factors and Impact on Clinical Outcomes After an Acute Coronary Syndrome, a Sub-study of the Randomized ANTARCTIC Trial | 1.8 | 9 | Citations (PDF) |
| 42 | Access routes in transcatheter aortic valve replacement: All roads lead to Rome but only one is paved | 1.1 | 1 | Citations (PDF) |
| 43 | Impact of target vessel choice on outcomes following percutaneous coronary intervention in patients with a prior coronary artery bypass graft | 1.1 | 3 | Citations (PDF) |
| 44 | Feasibility of measuring patient-reported health status at time of percutaneous coronary intervention: Results from a single-center quality-improvement initiative. | 1.5 | 1 | Citations (PDF) |
| 45 | Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial | 45.9 | 124 | Citations (PDF) |
| 46 | Severe acute respiratory syndrome coronavirus 2 and renin-angiotensin system blockers: A review and pooled analysis | 0.4 | 9 | Citations (PDF) |
| 47 | Diagnosis and Management of Acute Coronary Syndrome: What is New and Why? Insight From the 2020 European Society of Cardiology Guidelines | 1.8 | 19 | Citations (PDF) |
| 48 | Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review | 3.1 | 56 | Citations (PDF) |
| 49 | Blunting periprocedural myocardial necrosis: Rationale and design of the randomized ALPHEUS study | 1.8 | 11 | Citations (PDF) |
| 50 | Coronary Calcification and Long-Term Outcomes According to Drug-Eluting Stent Generation. | 1.9 | 153 | Citations (PDF) |
| 51 | Acute Multivessel Coronary Occlusion Revealing COVID-19 in a Young Adult | 0.2 | 10 | Citations (PDF) |
| 52 | Early Aspirin Discontinuation Following Acute Coronary Syndrome or Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials | 1.8 | 11 | Citations (PDF) |
| 53 | Effect of oral anticoagulation on clinical outcomes and haemodynamic variables after successful transcatheter aortic valve implantation | 0.4 | 6 | Citations (PDF) |
| 54 | Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry | 3.3 | 57 | Citations (PDF) |
| 55 | Combined and independent impact of coronary artery calcification and inflammation on risk for adverse cardiovascular events after percutaneous coronary intervention: Results from a large single-center registry | 1.1 | 1 | Citations (PDF) |
| 56 | The impact of chronic kidney disease in women undergoing transcatheter aortic valve replacement: Analysis from the Women's INternational Transcatheter Aortic Valve Implantation (WIN-TAVI) registry | 1.1 | 13 | Citations (PDF) |
| 57 | The importance of the Heart Team evaluation before transcatheter aortic valve replacement: Results from the BRAVO-3 trial | 1.1 | 1 | Citations (PDF) |
| 58 | Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk: A Patient-Level Stratified Analysis From Four Postapproval Studies | 13.2 | 34 | Citations (PDF) |
| 59 | Radial versus femoral artery access for percutaneous coronary artery intervention in patients with acute myocardial infarction and multivessel disease complicated by cardiogenic shock: Subanalysis from the CULPRIT-SHOCK trial | 1.8 | 25 | Citations (PDF) |
| 60 | Antithrombotic Therapy for Patients With Left Ventricular Mural Thrombus | 6.3 | 200 | Citations (PDF) |
| 61 | Sex‐Related Differences in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Intervention: A Patient‐Level Pooled Analysis From 4 Postapproval Studies | 3.1 | 30 | Citations (PDF) |
| 62 | Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis | 2.6 | 58 | Citations (PDF) |
| 63 | Prognostic Value of SYNTAX Score in Patients With Infarct-Related Cardiogenic Shock: Insights From the CULPRIT-SHOCK Trial. | 1.9 | 19 | Citations (PDF) |
| 64 | Impact of diabetes mellitus on short term vascular complications after TAVR: Results from the BRAVO-3 randomized trial | 1.6 | 14 | Citations (PDF) |
| 65 | Investigator Versus Core Laboratory Evaluation of Coronary Flow and Related Mortality in the CULPRIT-SHOCK Trial | 3.3 | 6 | Citations (PDF) |
| 66 | Small-vessel PCI outcomes in men, women, and minorities following platinum chromium everolimus-eluting stents: Insights from the pooled PLATINUM Diversity and PROMUS Element Plus Post-Approval studies | 1.1 | 12 | Citations (PDF) |
| 67 | Impact of percutaneous closure device type on vascular and bleeding complications after TAVR: A post hoc analysis from the BRAVO-3 randomized trial | 1.1 | 46 | Citations (PDF) |
| 68 | Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age | 1.9 | 17 | Citations (PDF) |
| 69 | Residual Inflammatory Risk in Patients With Low LDL Cholesterol Levels Undergoing Percutaneous Coronary Intervention | 6.3 | 118 | Citations (PDF) |
| 70 | Do Patients need Lifelong β-Blockers after an Uncomplicated Myocardial Infarction? | 1.8 | 32 | Citations (PDF) |
| 71 | Temporal Trends in Statin Prescriptions and Residual Cholesterol Risk in Patients With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention | 1.5 | 8 | Citations (PDF) |
| 72 | Elderly Patients with ST-Segment Elevation Myocardial Infarction: A Patient-Centered Approach | 2.3 | 18 | Citations (PDF) |
| 73 | The link between anemia and adverse outcomes in patients with acute coronary syndrome | 1.1 | 16 | Citations (PDF) |
| 74 | Epidemiology, treatment patterns and outcomes in patients with coronary or lower extremity artery disease in France | 0.4 | 16 | Citations (PDF) |
| 75 | Adjunct Pharmacotherapy After Transcatheter Aortic Valve ReplacementCurrent Status and Future Directions | 0.2 | 5 | Citations (PDF) |
| 76 | Incidence of, risk factors for and impact of readmission for heart failure after successful transcatheter aortic valve implantation | 0.4 | 22 | Citations (PDF) |
| 77 | Examining the role of diabetes mellitus in ST-elevation myocardial infarction | 1.1 | 1 | Citations (PDF) |
| 78 | Long-Term Mortality and Early Valve Dysfunction According to Anticoagulation Use: The FRANCE TAVI Registry. | 6.3 | 110 | Citations (PDF) |
| 79 | Antithrombotic Therapy After Transcatheter Aortic Valve Replacement | 3.3 | 77 | Citations (PDF) |
| 80 | Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention | 1.8 | 9 | Citations (PDF) |
| 81 | Impact of coronary artery disease and percutaneous coronary intervention in women undergoing transcatheter aortic valve replacement: From the WIN-TAVI registry | 1.1 | 30 | Citations (PDF) |
| 82 | Cardiac manifestations in sickle cell disease varies with patient genotype | 1.6 | 9 | Citations (PDF) |
| 83 | Periprocedural myocardial infarction and injury in elective coronary stenting | 7.2 | 187 | Citations (PDF) |
| 84 | Device-Related Thrombosis After Percutaneous Left Atrial Appendage Occlusion for Atrial Fibrillation. | 6.3 | 351 | Citations (PDF) |
| 85 | Non-vitamin K Antagonist Oral Anticoagulant After Acute Coronary Syndrome: Is There a Role? | 1.4 | 7 | Citations (PDF) |
| 86 | Non-femoral TAVR: Time to stratify alternative vascular approaches | 1.1 | 7 | Citations (PDF) |
| 87 | Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions | 7.2 | 143 | Citations (PDF) |
| 88 | Determinants of Significant Out-Of-Hospital Bleeding in Patients Undergoing Percutaneous Coronary Intervention | 2.3 | 21 | Citations (PDF) |
| 89 | Assessing and minimizing the risk of percutaneous coronary intervention in patients with chronic kidney disease | 1.1 | 18 | Citations (PDF) |
| 90 | Impact of Baseline Atrial Fibrillation on Outcomes Among Women Who Underwent Contemporary Transcatheter Aortic Valve Implantation (from the Win-TAVI Registry) | 1.5 | 23 | Citations (PDF) |
| 91 | Thrombus composition in sudden cardiac death from acute myocardial infarction | 2.0 | 27 | Citations (PDF) |
| 92 | Prevention and treatment of premature ischaemic heart disease with European Society of Cardiology Guidelines | 2.6 | 3 | Citations (PDF) |
| 93 | ABSTRACT NUMBER: ESOC2026A709 EFFECTS OF PERCUTANEOUS LEFT ATRIAL APPENDAGE CLOSURE FOR ATRIAL FIBRILLATION IN PATIENTS WITH INTRACEREBRAL HEMORRHAGE: A POOLED ANALYSIS OF INDIVIDUAL-PATIENT DATA FROM COHORT STUDIES | 2.9 | 0 | Citations (PDF) |
| 94 | Heart Rate and Cardiovascular Outcomes in Post-Myocardial Infarction Patients Treated by β-Blockers: A Secondary Analysis of the ABYSS Trial. | 13.2 | 1 | Citations (PDF) |
| 95 | Prognostic impact of pericardial effusion in patients with acute myocarditis. | 0.9 | 0 | Citations (PDF) |
| 96 | TAVR for Bicuspid Aortic Stenosis: Toward a More Appropriate Comparator? | 1.9 | 0 | Citations (PDF) |
